Safety Profile of Injectable Antipsychotic Medications

Neurological Side Effects

• Acute dystonia typically appears after the first few doses or dose increases of injectable antipsychotics. 1
• Laryngeal dystonia is a rare but potentially life‑threatening adverse event that can cause choking, breathing difficulty, or stridor. 1
• Akathisia usually emerges within the first few days of treatment. 1
• Early recognition of drug‑induced Parkinsonism improves the chance of complete recovery after rapid withdrawal. 1
• Tardive dyskinesia occurs in about 5 % of young patients per year, manifesting as involuntary facial and limb movements. 1
• Tardive dystonia, often accompanying tardive dyskinesia, presents as slow, disabling spasms along the body’s long axis. 2
• Atypical antipsychotics carry a lower overall risk of extrapyramidal symptoms than traditional neuroleptics; among atypicals, risperidone has the highest EPS risk. 3
• Neuroleptic malignant syndrome (NMS) presents with a tetrad of mental status change, fever, rigidity, and autonomic dysfunction; its incidence ranges from 0.02 % to 3 % with current mortality < 15 %. 1
• NMS can theoretically occur with any antipsychotic, including atypical agents. 3
• Antipsychotics lower the seizure threshold in a dose‑dependent manner; seizures are rare (< 1 %) at therapeutic doses but occur in ≈ 5 % of patients receiving high‑dose clozapine. 1
• Rapid escalation of dosage increases seizure risk. 2
• Traditional neuroleptics, especially low‑potency agents with anticholinergic activity, may cause sedation, cognitive blunting, apathy, and memory deficits. 2
• Atypical antipsychotics consistently improve fine‑motor function, memory, and executive function compared with traditional neuroleptics. 3

Metabolic Side Effects

• Weight gain is the most common significant metabolic problem associated with atypical injectable antipsychotics and can be extreme in some patients. 3
• Hyperglycemia is a documented metabolic adverse effect of injectable antipsychotics. 1

Cardiac Side Effects

• Almost all antipsychotics produce some degree of QT‑interval prolongation via a quinidine‑like effect. 4
• Thioridazine and droperidol carry FDA black‑box warnings for QT prolongation, torsades de pointes, and sudden death. 4
• Mean QT prolongation (milliseconds) varies by agent: thioridazine 25‑30 ms, ziprasidone 5‑22 ms, haloperidol 7 ms, risperidone 0‑5 ms, aripiprazole 0 ms. 4
• Youth may be more susceptible to cardiac effects of antipsychotics. 3
• Orthostatic hypotension is a significant problem with several injectable agents. 3
• Tachycardia has been documented with clozapine use. 2

Hematologic & Hepatic Monitoring

• Clozapine‑induced agranulocytosis occurs in approximately 1 % of patients; it is potentially fatal but usually reversible if the drug is stopped promptly. 2
• Agranulocytosis can occur with any antipsychotic, though it is primarily associated with clozapine. 3
• Clozapine monitoring protocol: weekly complete blood count (CBC) for the first 6 months, then every 2 weeks, and continued for 4 weeks after discontinuation. 3
• Case reports describe leukocytopenia in teenagers receiving risperidone. 3
• Quetiapine has been linked to abrupt drops in absolute neutrophil count and platelet count. 3
• Atypical agents may cause transient elevations in hepatic transaminases, which generally resolve after drug cessation. 3
• Baseline liver‑function testing and periodic monitoring are recommended before and during treatment with injectable antipsychotics. 3
• Phenothiazines can cause cholestatic jaundice. 2

Ocular Considerations

• Quetiapine produced cataracts in canine studies; the FDA recommends a baseline eye examination and a follow‑up at 6 months when prescribing quetiapine. 3
• Thioridazine may cause lenticular stippling. 2

Common Adverse Effects

• Sedation is frequently reported with many injectable antipsychotics. 3
• Activation (agitation, restlessness) can occur with several agents. 3
• Dizziness is a commonly noted side effect. 3
• Hypersalivation is especially associated with clozapine. 2
• Fever is particularly reported with clozapine. 2
• Sexual dysfunction and hyperprolactinemia are documented adverse effects. 2
• Phenothiazines may cause photosensitivity. 2
• Somnolence, anxiety, agitation, oral hypoesthesia, headache, nausea, vomiting, insomnia, and tremor have been observed with various atypical injectable antipsychotics. 1

Risperidone‑Induced Bradycardia: Guideline Recognition and Management

Guideline Recognition

• The 2018 ACC/AHA/HRS Guideline on Bradycardia and Cardiac Conduction Delay lists risperidone as a medication that can cause potentially reversible sinus node dysfunction (SND) and bradycardia. 5
• Risperidone is grouped with beta‑blockers, non‑dihydropyridine calcium‑channel blockers, digoxin, and other anti‑arrhythmic drugs as recognized causes of drug‑induced bradycardia. 5
• For symptomatic patients with SND, the guideline recommends evaluating and treating reversible causes, including discontinuation of offending agents such as risperidone. 5

Cardiac Electrophysiology Effects

• Risperidone produces minimal to mild QT‑interval prolongation (average 0–5 ms), which is markedly less than thioridazine (≈25–30 ms) or ziprasidone (≈5–22 ms). 6
• Almost all antipsychotics exert a quinidine‑like effect on cardiac ion channels, leading to some degree of QT prolongation; risperidone’s effect is relatively low within this class. 6

Clinical Assessment and Acute Management

• Immediate assessment (European Heart Journal 2014) for bradycardia in patients receiving risperidone includes:
• First‑line acute therapy: Atropine 0.5–1 mg IV, repeat every 3–5 min as needed, up to a total of 1.5–3 mg. (Class I recommendation, Circulation 2010). 7
• Second‑line therapy (if atropine ineffective):
• Refractory cases: Consider transcutaneous pacing. (Circulation 2010). 7

Definitive Management and Medication Strategies

• Discontinue or reduce the risperidone dose because it is a reversible cause of sinus node dysfunction. (Pediatrics 2008 guideline). [8][5]
• Evaluate for additional contributors to bradycardia such as hypothermia, electrolyte disturbances, hypothyroidism, or interacting medications. (ACC/AHA/HRS). 5
• When a lower‑risk antipsychotic is needed, consider agents like aripiprazole, which is associated with negligible QT prolongation (≈0 ms). (Pediatrics 2016). 6

Monitoring Recommendations

• Obtain a baseline ECG before initiating risperidone, especially in high‑risk groups (elderly, females, patients with pre‑existing cardiac disease). (European Heart Journal 2014). 9
• Perform periodic ECG monitoring during chronic therapy, particularly after dose escalation. (European Heart Journal 2014). 9
• Avoid co‑administration of other QT‑prolonging or bradycardia‑inducing drugs without specialist consultation. (Pediatrics 2008). [10][8]

Clinical Significance

• Although risperidone‑related bradycardia is less common than its other cardiac effects (e.g., tachycardia, orthostatic hypotension), it can be severe and symptomatic, warranting vigilance in vulnerable populations. (ACC/AHA/HRS and Pediatrics 2016). [5][6]